A

Apontis Pharma AG
XETRA:APPH

Watchlist Manager
Apontis Pharma AG
XETRA:APPH
Watchlist
Price: 9.64 EUR -1.43% Market Closed
Market Cap: 80.3m EUR
Have any thoughts about
Apontis Pharma AG?
Write Note

Intrinsic Value

The intrinsic value of one APPH stock under the Base Case scenario is 15.03 EUR. Compared to the current market price of 9.64 EUR, Apontis Pharma AG is Undervalued by 36%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

APPH Intrinsic Value
15.03 EUR
Undervaluation 36%
Intrinsic Value
Price
A
Worst Case
Base Case
Best Case

Valuation Backtest
Apontis Pharma AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for APPH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about APPH?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Apontis Pharma AG

Provide an overview of the primary business activities
of Apontis Pharma AG.

What unique competitive advantages
does Apontis Pharma AG hold over its rivals?

What risks and challenges
does Apontis Pharma AG face in the near future?

Has there been any significant insider trading activity
in Apontis Pharma AG recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Apontis Pharma AG.

Provide P/S
for Apontis Pharma AG.

Provide P/E
for Apontis Pharma AG.

Provide P/OCF
for Apontis Pharma AG.

Provide P/FCFE
for Apontis Pharma AG.

Provide P/B
for Apontis Pharma AG.

Provide EV/S
for Apontis Pharma AG.

Provide EV/GP
for Apontis Pharma AG.

Provide EV/EBITDA
for Apontis Pharma AG.

Provide EV/EBIT
for Apontis Pharma AG.

Provide EV/OCF
for Apontis Pharma AG.

Provide EV/FCFF
for Apontis Pharma AG.

Provide EV/IC
for Apontis Pharma AG.

Show me price targets
for Apontis Pharma AG made by professional analysts.

What are the Revenue projections
for Apontis Pharma AG?

How accurate were the past Revenue estimates
for Apontis Pharma AG?

What are the Net Income projections
for Apontis Pharma AG?

How accurate were the past Net Income estimates
for Apontis Pharma AG?

What are the EPS projections
for Apontis Pharma AG?

How accurate were the past EPS estimates
for Apontis Pharma AG?

What are the EBIT projections
for Apontis Pharma AG?

How accurate were the past EBIT estimates
for Apontis Pharma AG?

Compare the revenue forecasts
for Apontis Pharma AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Apontis Pharma AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Apontis Pharma AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Apontis Pharma AG compared to its peers.

Compare the P/E ratios
of Apontis Pharma AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Apontis Pharma AG with its peers.

Analyze the financial leverage
of Apontis Pharma AG compared to its main competitors.

Show all profitability ratios
for Apontis Pharma AG.

Provide ROE
for Apontis Pharma AG.

Provide ROA
for Apontis Pharma AG.

Provide ROIC
for Apontis Pharma AG.

Provide ROCE
for Apontis Pharma AG.

Provide Gross Margin
for Apontis Pharma AG.

Provide Operating Margin
for Apontis Pharma AG.

Provide Net Margin
for Apontis Pharma AG.

Provide FCF Margin
for Apontis Pharma AG.

Show all solvency ratios
for Apontis Pharma AG.

Provide D/E Ratio
for Apontis Pharma AG.

Provide D/A Ratio
for Apontis Pharma AG.

Provide Interest Coverage Ratio
for Apontis Pharma AG.

Provide Altman Z-Score Ratio
for Apontis Pharma AG.

Provide Quick Ratio
for Apontis Pharma AG.

Provide Current Ratio
for Apontis Pharma AG.

Provide Cash Ratio
for Apontis Pharma AG.

What is the historical Revenue growth
over the last 5 years for Apontis Pharma AG?

What is the historical Net Income growth
over the last 5 years for Apontis Pharma AG?

What is the current Free Cash Flow
of Apontis Pharma AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Apontis Pharma AG.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Apontis Pharma AG

Current Assets 23.4m
Cash & Short-Term Investments 14.3m
Receivables 2.7m
Other Current Assets 6.4m
Non-Current Assets 22m
Other Non-Current Assets 22m
Current Liabilities 6.2m
Other Current Liabilities 6.2m
Non-Current Liabilities 8.1m
Other Non-Current Liabilities 8.1m
Efficiency

Earnings Waterfall
Apontis Pharma AG

Revenue
63.8m EUR
Cost of Revenue
-25.4m EUR
Gross Profit
38.5m EUR
Operating Expenses
-47.1m EUR
Operating Income
-8.7m EUR
Other Expenses
2.1m EUR
Net Income
-6.6m EUR

Free Cash Flow Analysis
Apontis Pharma AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

APPH Profitability Score
Profitability Due Diligence

Apontis Pharma AG's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Negative Operating Income
Negative ROE
29/100
Profitability
Score

Apontis Pharma AG's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

APPH Solvency Score
Solvency Due Diligence

Apontis Pharma AG's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
High Altman Z-Score
59/100
Solvency
Score

Apontis Pharma AG's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

APPH Price Targets Summary
Apontis Pharma AG

Wall Street analysts forecast APPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for APPH is 13.52 EUR with a low forecast of 10.1 EUR and a high forecast of 17.85 EUR.

Lowest
Price Target
10.1 EUR
5% Upside
Average
Price Target
13.52 EUR
40% Upside
Highest
Price Target
17.85 EUR
85% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for APPH?

Click here to dive deeper.

Dividends

Apontis Pharma AG
does not pay dividends
Shareholder Yield

Current shareholder yield for APPH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

APPH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Apontis Pharma AG

Country

Germany

Industry

Pharmaceuticals

Market Cap

80.3m EUR

Dividend Yield

0%

Description

APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.

Contact

NORDRHEIN-WESTFALEN
Monheim Am Rhein
Alfred-Nobel-Strasse 10

IPO

2021-05-11

Employees

176

Officers

CEO & Chairman of Management Board
Mr. Bruno Wohlschlegel
Chief Product Officer & Deputy Chairman of Management Board
Mr. Thomas Milz
CFO & Member of Management Board
Mr. Thomas Zimmermann
Head of Marketing
Mr. Harald Weyand
Head of HR
Ms. Susanne Böhm
Head of Medicine
Dr. Olaf Randerath
Show More
Head of QA, Drug Safety & Regulatory Affairs
Dr. Susanne Endreß
Show Less

See Also

Discover More
What is the Intrinsic Value of one APPH stock?

The intrinsic value of one APPH stock under the Base Case scenario is 15.03 EUR.

Is APPH stock undervalued or overvalued?

Compared to the current market price of 9.64 EUR, Apontis Pharma AG is Undervalued by 36%.

Back to Top